Advertisement

Does A Therapy for Reflex Vasovagal Syncope Really Exist?

  • Simone RomanoEmail author
  • Lorella Branz
  • Luigi Fondrieschi
  • Pietro Minuz
Review article

Abstract

Syncope is a temporary loss of consciousness due to transient global cerebral hypoperfusion. Reflex syncope is the most frequent, representing 21% of all types of syncopal events, and includes: (a) the vasovagal syncope (classical type); (b) the situational syncope; (c) the carotid sinus syncope and (d) non-classical forms. An accurate anamnesis and physical examination are fundamental for the diagnosis. Although limited evidence is available regarding the efficacy of some treatments, a number of these can be successfully used in the clinical practice. It is, however, important to personalize the therapeutic approach in order to achieve an efficient reduction or suppression of syncopal episodes. Patients should be reassured about the benignity of these events and the possibility of reducing their frequency over time. They should be also educated on how to recognize and abort incoming syncopal episodes. Patients may be advised to increase their introit in water and salt, as well as to reduce vasoactive medications, if no contraindications exist. Orthostatic training may be beneficial but only in very motivated young patients capable of strictly adhering to the exercise plan. So far, any proposed pharmacological treatment has demonstrated very limited efficacy and, therefore, it should be tried in case of failure of non-pharmacological approaches. Pacemaker implantation is clearly indicated in patients with documented cardioinhibitory syncope in the absence of a vasodepressor component, which can compromise their quality of life. Despite the American and European guidelines for the treatment of syncope are similar, still some differences can be denoted. Aim of this study is to evaluate the management of patients with recurrent syncopal episodes focusing on pharmacological and non-pharmacological approaches.

Keywords

Reflex syncope Vasovagal syncope Treatment Pacemaker American and European guidelines Blood pressure 

Notes

Compliance with Ethical Standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical Approval

This article does not contain any studies with animals performed by any of the authors.

References

  1. 1.
    Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martín A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG, ESC Scientific Document Group. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J. 2018;39(21):1883–948.  https://doi.org/10.1093/eurheartj/ehy037.CrossRefGoogle Scholar
  2. 2.
    da Silva RMFL. Syncope: epidemiology, etiology, and prognosis. Front Physiol. 2014;5:471.  https://doi.org/10.3389/fphys.2014.00471.CrossRefGoogle Scholar
  3. 3.
    Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, Levy D. Incidence and prognosis of syncope. N Engl J Med. 2002;347:878–85.CrossRefGoogle Scholar
  4. 4.
    Mosqueda-Garcia R, Furlan R, Tank J, Fernandez-Violante R. The elusive pathophysiology of neurally mediated syncope. Circulation. 2000;102:2898–906.CrossRefGoogle Scholar
  5. 5.
    Morillo CA, Eckberg DL, Ellenbogen KA, Beightol LA, Hoag JB, Tahvanainen KU, Kuusela TA, Diedrich AM. Vagal and sympathetic mechanisms in patients with orthostatic vasovagal syncope. Circulation. 1997;96:2509–13.CrossRefGoogle Scholar
  6. 6.
    Alboni P. The different clinical presentations of vasovagal syncope. Heart. 2015;101:674–8.CrossRefGoogle Scholar
  7. 7.
    Deharo JC, Guieu R, Mechulan A, Peyrouse E, Kipson N, Ruf J, Gerolami V, Devoto G, Marre V, Brignole M. Syncope without prodromes in patients with normal heart and normal electrocardiogram: a distinct entity. J Am Coll Cardiol. 2013;62:1075–80.CrossRefGoogle Scholar
  8. 8.
    Brignole M, Deharo JC, De Roy L, Menozzi C, Blommaert D, Dabiri L, Ruf J, Guieu R. Syncope due to idiopathic paroxysmal atrioventricular block: longterm follow-up of a distinct form of atrioventricular block. J Am Coll Cardiol. 2011;58:167–73.CrossRefGoogle Scholar
  9. 9.
    Guieu R, Deharo JC, Ruf J, Mottola G, Kipson N, Bruzzese L, Gerolami V, Franceschi F, Ungar A, Tomaino M, Iori M, Brignole M. Adenosine and clinical forms of neurally-mediated syncope. J Am Coll Cardiol. 2015;66:204–5.CrossRefGoogle Scholar
  10. 10.
    Blanc JJ. Clinical laboratory testing: what is the role of tilt-table testing, active standing test, carotid massage, electrophysiological testing and ATP test in the syncope evaluation? Prog Cardiovasc Dis. 2013;55(4):418–24.  https://doi.org/10.1016/j.pcad.2012.11.002.CrossRefGoogle Scholar
  11. 11.
    Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS Guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. J Am Coll Cardiol. 2017;70:620.CrossRefGoogle Scholar
  12. 12.
    Brignole M, Ammirati F, Arabia F, Quartieri F, Tomaino M, Ungar A, Lunati M, Russo V, Del Rosso A, Gaggioli G, Syncope Unit Project (SUP) Two Investigators. Assessment of a standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncopes. Eur Heart J. 2015;36:1529–35.CrossRefGoogle Scholar
  13. 13.
    El-Sayed H, Hainsworth R. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope. Heart. 1996;75:134–40.CrossRefGoogle Scholar
  14. 14.
    Romme JJ, Reitsma JB, Go-Schön IK, Harms MP, Ruiter JH, Luitse JS, Lenders JW, Wieling W, van Dijk N. Prospective evaluation of non-pharmacological treatment in vasovagal syncope. Europace. 2010;12(4):567–73.  https://doi.org/10.1093/europace/eup414.CrossRefGoogle Scholar
  15. 15.
    Brignole M, Croci F, Menozzi C, Solano A, Donateo P, Oddone D, Puggioni E, Lolli G. Isometric arm counter-pressure maneuvers to abort impending vasovagal syncope. J Am Coll Cardiol. 2002;40:2053–9.CrossRefGoogle Scholar
  16. 16.
    Krediet CT, van Dijk N, Linzer M, van Lieshout JJ, Wieling W. Management of vasovagal syncope: controlling or aborting faints by leg crossing and muscle tensing. Circulation. 2002;106:1684–9.CrossRefGoogle Scholar
  17. 17.
    Kim KH, Cho JG, Lee KO, Seo TJ, Shon CY, Lim SY, Yun KH, Sohn IS, Hong YJ, Park HW, Kim JH, Kim W, Ahn YK, Jeong MH, Park JC, Kang JC. Usefulness of physical maneuvers for prevention of vasovagal syncope. Circ J. 2005;69:1084–8.CrossRefGoogle Scholar
  18. 18.
    Van Dijk N, Quartieri F, Blanc JJ, Garcia-Civera R, Brignole M, Moya A, Wieling W, PCTrial Investigators. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol. 2006;48:1652–7.CrossRefGoogle Scholar
  19. 19.
    Tomaino M, Romeo C, Vitale E, Kus T, Moya A, van Dijk N, Giuli S, D’Ippolito G, Gentili A, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE 3) Investigators. Physical counter-pressure manoeuvres in preventing syncopal recurrence in patients older than 40 years with recurrent neurally mediated syncope: a controlled study from the Third International Study on Syncope of Uncertain Etiology (ISSUE-3). Europace. 2014;16:1515–20.CrossRefGoogle Scholar
  20. 20.
    Mtinangi B, Hainsworth R. Increased orthostatic tolerance following moderate exercise training in patients with unexplained syncope. Heart. 1998;80:596–600.CrossRefGoogle Scholar
  21. 21.
    Reybrouck T, Heidbuchel H, Van De Werf F, Ector H. Long-term follow-up results of tilt training therapy in patients with recurrent neurocardiogenic syncope. Pacing Clin Electrophysiol. 2002;25:1441–6.CrossRefGoogle Scholar
  22. 22.
    Di Girolamo E, Di Iorio C, Leonzio L, et al. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: a controlled study. Circulation. 1999;100:1798.CrossRefGoogle Scholar
  23. 23.
    Zeng H, Ge K, Zhang W, Wang G, Guo L. The effect of orthostatic training in the prevention of vasovagal syncope and its influencing factors. Int Heart J. 2008;49:707–12.CrossRefGoogle Scholar
  24. 24.
    Jang WJ, Yim HR, Lee SH, Park SJ, Kim JS, On YK. Prognosis after tilt training in patients with recurrent vasovagal syncope. Int J Cardiol. 2013;168:4264–5.CrossRefGoogle Scholar
  25. 25.
    Foglia-Manzillo G, Giada F, Gaggioli G, Bartoletti A, Lolli G, Dinelli M, Del Rosso A, Santarone M, Raviele A, Brignole M. Efficacy of tilt training in the treatment of neurally mediated syncope. A randomized study. Europace. 2004;6:199–204.CrossRefGoogle Scholar
  26. 26.
    Kinay O, Yazici M, Nazli C, Acar G, Gedikli O, Altinbas A, Kahraman H, Dogan A, Ozaydin M, Tuzun N, Ergene O. Tilt training for recurrent neurocardiogenic syncope: effectiveness, patient compliance, and scheduling the frequency of training sessions. Jpn Heart J. 2004;45:833–43.CrossRefGoogle Scholar
  27. 27.
    Gurevitz O, Barsheshet A, Bar-Lev D, et al. Tilt training: does it have a role in preventing vasovagal syncope? Pacing Clin Electrophysiol. 2007;30:1499.CrossRefGoogle Scholar
  28. 28.
    On YK, Park J, Huh J, Kim JS. Is home orthostatic self-training effective in preventing neurally mediated syncope? Pacing Clin Electrophysiol. 2007;30:638–43.CrossRefGoogle Scholar
  29. 29.
    Duygu H, Zoghi M, Turk U, Akyuz S, Ozerkan F, Akilli A, Erturk U, Onder R, Akin M. The role of tilt training in preventing recurrent syncope in patients with vasovagal syncope: a prospective and randomized study. Pacing Clin Electrophysiol. 2008;31:592–6.CrossRefGoogle Scholar
  30. 30.
    Connolly SJ, Sheldon R, Thorpe KE, et al. Pacemaker therapy for prevention of syncope in patients with recurrent severe vasovagal syncope: Second Vasovagal Pacemaker Study (VPS II): a randomized trial. JAMA. 2003;289:2224.CrossRefGoogle Scholar
  31. 31.
    Sud S, Massel D, Klein GJ, et al. The expectation effect and cardiac pacing for refractory vasovagal syncope. Am J Med. 2007;120:54.CrossRefGoogle Scholar
  32. 32.
    Evidence Review Committee Members, Varosy PD, Chen LY, et al. Pacing as a treatment for reflex-mediated (vasovagal, situational, or carotid sinus hypersensitivity) syncope: a systematic review for the 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2017;2017(14):e255.Google Scholar
  33. 33.
    Brignole M, Menozzi C, Moya A, Andresen D, Blanc JJ, Krahn AD, Wieling W, Beiras X, Deharo JC, Russo V, Tomaino M, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Pacemaker therapy in patients with neurally mediated syncope and documented asystole: Third International Study on Syncope of Uncertain Etiology (ISSUE-3): a randomized trial. Circulation. 2012;125:2566–71.CrossRefGoogle Scholar
  34. 34.
    Brignole M, Deharo JC, Menozzi C, et al. The benefit of pacemaker therapy in patients with neurally mediated syncope and documented asystole: a meta-analysis of implantable loop recorder studies. Europace. 2018;20:1362.CrossRefGoogle Scholar
  35. 35.
    Sutton R, Brignole M. Twenty-eight years of research permit reinterpretation of tilt-testing: hypotensive susceptibility rather than diagnosis. Eur Heart J. 2014;35:2211–2.CrossRefGoogle Scholar
  36. 36.
    Brignole M, Donateo P, Tomaino M, Massa R, Iori M, Beiras X, Moya A, Kus T, Deharo JC, Giuli S, Gentili A, Sutton R, International Study on Syncope of Uncertain Etiology 3 (ISSUE-3) Investigators. Benefit of pacemaker therapy in patients with presumed neurally mediated syncope and documented asystole is greater when tilt test is negative: an analysis from the third International Study on Syncope of Uncertain Etiology (ISSUE-3). Circ Arrhythm Electrophysiol. 2014;7:10–6.CrossRefGoogle Scholar
  37. 37.
    Brignole M, Deharo JC, Menozzi C, Moya A, Sutton R, Tomaino M, Ungar A. The benefit of pacemaker therapy in patients with neurally mediated syncope and documented asystole: a meta-analysis of implantable loop recorder studies. Europace. 2018;20(8):1362–6.  https://doi.org/10.1093/europace/eux321.CrossRefGoogle Scholar
  38. 38.
    Saal DP, Thijs RD, van Zwet EW, Bootsma M, Brignole M, Benditt DG, van Dijk JG. Temporal relationship of asystole to onset of transient loss of consciousness in tilt-induced reflex syncope. JACC Clin Electrophysiol. 2017;3:1592–8.CrossRefGoogle Scholar
  39. 39.
    Brignole M, Arabia F, Ammirati F, et al. Standardized algorithm for cardiac pacing in older patients affected by severe unpredictable reflex syncope: 3-year insights from the Syncope Unit Project 2 (SUP 2) study. Europace. 2016;18(9):1427–33.  https://doi.org/10.1093/europace/euv343 (Epub 2015 Nov 26).CrossRefGoogle Scholar
  40. 40.
    Brignole M, Menozzi C, Lolli G, Bottoni N, Gaggioli G. Long-term outcome of paced and non-paced patients with severe carotid sinus syndrome. Am J Cardiol. 1992;69:1039–43.CrossRefGoogle Scholar
  41. 41.
    Lopes R, Gonçalves A, Campos J, Frutuoso C, Silva A, Touguinha C, Freitas J, Maciel MJ. The role of pacemaker in hypersensitive carotid sinus syndrome. Europace. 2011;13(4):572–5.  https://doi.org/10.1093/europace/euq455.CrossRefGoogle Scholar
  42. 42.
    Gaggioli G, Brignole M, Menozzi C, Devoto G, Oddone D, Gianfranchi L, Gostoli E, Bottoni N, Lolli G. A positive response to head-up tilt testing predicts syncopal recurrence in carotid sinus syndrome patients with permanent pacemakers. Am J Cardiol. 1995;76:720–2.CrossRefGoogle Scholar
  43. 43.
    SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood pressure control. N Engl J Med. 2015;373:2103–16.CrossRefGoogle Scholar
  44. 44.
    Solari D, Tesi F, Unterhuber M, Gaggioli G, Ungar A, Tomaino M, Brignole M. Stop vasodepressor drugs in reflex syncope: a randomised controlled trial. Heart. 2017;103:449–55.CrossRefGoogle Scholar
  45. 45.
    Brignole M, Menozzi C, Gaggioli G, Musso G, Foglia-Manzillo G, Mascioli G, Fradella G, Bottoni N, Mureddu R. Effects of long-term vasodilator therapy in patients with carotid sinus hypersensitivity. Am Heart J. 1998;136:264–8.CrossRefGoogle Scholar
  46. 46.
    Salim MA, Di Sessa TG. Effectiveness of fludrocortisone and salt in preventing syncope recurrence in children: a double-blind, placebo-controlled, randomized trial. J Am Coll Cardiol. 2005;45:484–8.CrossRefGoogle Scholar
  47. 47.
    Sheldon R, Raj SR, Rose MS, Morillo CA, Krahn AD, Medina E, Talajic M, Kus T, Seifer CM, Lelonek M, Klingenheben T, Parkash R, Ritchie D, McRae M, Sheldon RS, Rose SM, Ritchie DA, McCrae M, Morillo C, Malcolm VM, Krahn AD, Spindler B, Medina E, Talajic M, Kus T, Langlois A, Lelonek M, Raj S, Seifer C, Gardner M, Romeo M, Poirier P, Simpson C, Abdollah H, Reynolds J, Dorian P, Birnie D, Giuffre M, Gilligan D, Benditt D, Sheldon RS, Raj SR, Rose MS, Krahn A, Morillo C, Medina E. Fludrocortisone for the prevention of vasovagal syncope: a randomized, placebo-controlled trial. J Am Coll Cardiol. 2016;68(1):1–9.  https://doi.org/10.1016/j.jacc.2016.04.030 (ISSN 0735-1097).CrossRefGoogle Scholar
  48. 48.
    Raviele A, Brignole M, Sutton R, Alboni P, Giani P, Menozzi C, Moya A, for Vasovagal Syncope International Study (VASIS) Investigators. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncopea double-blind, randomized, placebo-controlled trial. Circulation. 1999;99:1452–7.CrossRefGoogle Scholar
  49. 49.
    Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart. 1998;79:45.CrossRefGoogle Scholar
  50. 50.
    Mitro P, Trejbal D, Rybár AR. Midodrine hydrochloride in the treatment of vasovagal syncope. Pacing Clin Electrophysiol. 1999;22:1620.CrossRefGoogle Scholar
  51. 51.
    Klingenheben T, Credner S, Hohnloser SH. Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. Pacing Clin Electrophysiol. 1999;22:276.CrossRefGoogle Scholar
  52. 52.
    Izcovich A, Malla CG, Manzotti M, Catalano HN, Guyatt G. Midodrine for orthostatic hypotension and recurrent reflex syncope: a systematic review. Neurology. 2014;83:1170–7.CrossRefGoogle Scholar
  53. 53.
    Romme JJCM, van Dijk N, Go-Schön IK, Reitsma JB, Wieling W. Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial). Europace. 2011;13:1639–47.CrossRefGoogle Scholar
  54. 54.
    Cox MM, Perlman BA, Mayor MR, et al. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope. J Am Coll Cardiol. 1995;26:1293.CrossRefGoogle Scholar
  55. 55.
    Natale A, Sra J, Dhala A, et al. Efficacy of different treatment strategies for neurocardiogenic syncope. Pacing Clin Electrophysiol. 1995;18:655.CrossRefGoogle Scholar
  56. 56.
    Ventura R, Maas R, Zeidler D, et al. A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test. Pacing Clin Electrophysiol. 2002;25:816.CrossRefGoogle Scholar
  57. 57.
    Flevari P, Livanis EG, Theodorakis GN, et al. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients’ well-being. J Am Coll Cardiol. 2002;40:499.CrossRefGoogle Scholar
  58. 58.
    Madrid AH, Ortega J, Rebollo JG, Manzano JG, Segovia JG, Sanchez A, Pena G, Moro C. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol. 2001;37:554–9.CrossRefGoogle Scholar
  59. 59.
    Sheldon R, Connolly S, Rose S, Klingenheben T, Krahn A, Morillo C, Talajic M, Ku T, Fouad-Tarazi F, Ritchie D, Koshman ML, POST Investigators. Prevention of syncope trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation. 2006;113:1164–74.CrossRefGoogle Scholar
  60. 60.
    Theodorakis GN, Leftheriotis D, Livanis EG, et al. Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace. 2006;8:193.CrossRefGoogle Scholar
  61. 61.
    Canney M, O’Connell MD, Murphy CM, et al. Single agent antihypertensive therapy and orthostatic blood pressure behaviour in older adults using beat-to-beat measurements: the Irish Longitudinal Study on Ageing. PLoS One. 2016;11(1):e0146156.  https://doi.org/10.1371/journal.pone.0146156.CrossRefGoogle Scholar
  62. 62.
    Sheldon RS, Morillo CA, Klingenheben T, et al. Age-dependent effect of beta-blockers in preventing vasovagal syncope. Circ Arrhythm Electrophysiol. 2012;5:920–6.CrossRefGoogle Scholar
  63. 63.
    Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999;33:1227–30.CrossRefGoogle Scholar
  64. 64.
    Grubb BP, Wolfe DA, Samoil D, et al. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope. Pacing Clin Electrophysiol. 1993;16(3 Pt 1):458–64.CrossRefGoogle Scholar
  65. 65.
    Márquez MF, Urias-Medina K, Gómez-Flores J, Sobrino A, Sotomayor-González A, González-Hermosillo A, Cárdenas M. Comparison of metoprolol vs clonazepam as a first treatment choice among patients with neurocardiogenic syncope. Gac Med Mex. 2008;144(6):503–7.Google Scholar
  66. 66.
    Milstein S, Buetikofer J, Dunnigan A, et al. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia. Am J Cardiol. 1990;65:1339.CrossRefGoogle Scholar
  67. 67.
    Kelly PA, Mann DE, Adler SW, et al. Low dose disopyramide often fails to prevent neurogenic syncope during head-up tilt testing. Pacing Clin Electrophysiol. 1994;17:573.CrossRefGoogle Scholar
  68. 68.
    Morillo CA, Leitch JW, Yee R, Klein GJ. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally mediated syncope induced by head-up tilt. J Am Coll Cardiol. 1993;22:1843.CrossRefGoogle Scholar
  69. 69.
    Grubb BP, Kosinski D, Mouhaffel A, Pothoulakis A. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope. Pacing Clin Electrophysiol. 1996;19:836.CrossRefGoogle Scholar
  70. 70.
    Nelson SD, Stanley M, Love CJ, et al. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope. Arch Intern Med. 1991;151:2425.CrossRefGoogle Scholar
  71. 71.
    Zeng C, Zhu Z, Liu G, et al. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope. Am Heart J. 1998;136:852.CrossRefGoogle Scholar
  72. 72.
    Brignole M, Guieu R, Tomaino M, Iori M, Ungar A, Bertolone C, Unterhuber M, Bottoni N, Tesi F, Claude Deharo J. Mechanism of syncope without prodromes with normal heart and normal electrocardiogram. Heart Rhythm. 2017;14:234–9.CrossRefGoogle Scholar
  73. 73.
    Kanjwal K, Saeed B, Karabin B, Kanjwal Y, Grubb BP. Use of octreotide in the treatment of refractory orthostatic intolerance. Am J Ther. 2012;19:7–10.CrossRefGoogle Scholar
  74. 74.
    Schroeder C, Birkenfeld AL, Mayer AF, Tank J, Diedrich A, Luft FC, Jordan J. Norepinephrine transporter inhibition prevents tilt-induced pre-syncope. J Am Coll Cardiol. 2006;48:516–22.CrossRefGoogle Scholar
  75. 75.
    Sheldon RS, Ritchie D, McRae M, Raj S. Norepinephrine transport inhibition for treatment of vasovagal syncope. J Cardiovasc Electrophysiol. 2013;24:799–803.CrossRefGoogle Scholar
  76. 76.
    Pachon JC, Pachon EI, Cunha Pachon MZ, Lobo TJ, Pachon JC, Santillana TG. Catheter ablation of severe neurally meditated reflex (neurocardiogenic or vasovagal) syncope: cardioneuroablation long-term results. Europace. 2011;13(9):1231–42.CrossRefGoogle Scholar
  77. 77.
    Yao Y, Shi R, Wong T, Zheng L, Chen W, Yang L, Huang W, Bao J, Zhang S. Endocardial autonomic denervation of the left atrium to treat vasovagal syncope: an early experience in human. Circ Arrhythm Electrophysiol. 2012;5(2):279–86.  https://doi.org/10.1161/CIRCEP.111.966465 (Epub 2012 Jan 24).CrossRefGoogle Scholar
  78. 78.
    Liang Z, Jiayou Z, Zonggui W, Dening L. Selective atrial vagal denervation guided by evoked vagal reflex to treat refractory vasovagal syncope. Pacing Clin Electrophysiol. 2012;35(7):e214–8.  https://doi.org/10.1111/j.1540-8159.2011.03320.x (Epub 2012 Feb 3).CrossRefGoogle Scholar

Copyright information

© Italian Society of Hypertension 2019

Authors and Affiliations

  • Simone Romano
    • 1
    Email author
  • Lorella Branz
    • 1
  • Luigi Fondrieschi
    • 1
  • Pietro Minuz
    • 1
  1. 1.Syncope Unit, Section of General Medicine and Hypertension, Department of MedicineUniversity of Verona, Policlinico GB RossiVeronaItaly

Personalised recommendations